HC
TEVA icon

Henshaw Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Henshaw Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-269,120
Closed -$8.94M – 307
2017
Q2 		$8.94M Hold
269,120
– – 0.94% 39
2017
Q1 		$8.64M Sell
269,120
-6,856
-2% -$234K 0.94% 40
2016
Q4 		$10M Buy
275,976
+954
+0.3% +$38.1K 1.18% 35
2016
Q3 		$12.7M Sell
275,022
-4,993
-2% -$261K 1.56% 27
2016
Q2 		$14.1M Sell
280,015
-992
-0.4% -$52.8K 1.83% 21
2016
Q1 		$15M Buy
+281,007
New +$16.5M 2% 19

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Henshaw Capital's TEVA Position: Q3 2017 in Review

Henshaw Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 269,120 shares — an estimated $8.94M sold.

Henshaw Capital first reported a position in TEVA in Q1 2016 and held it in 6 quarters. The position peaked at $15M in Q1 2016. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Henshaw Capital reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Henshaw Capital sold 269,120 Teva Pharmaceuticals shares in Q3 2017, an estimated $8.94M.
  • Henshaw Capital first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • Henshaw Capital's Teva Pharmaceuticals position peaked at $15M in Q1 2016.
  • 537 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Henshaw Capital's 13F filing for Q3 2017, filed 28 May 2026.